Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
26 sept. 2018 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at H.C. Wainwright Global Investment Conference
30 août 2018 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference
07 août 2018 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06 août 2018 16h05 HE
|
Kura Oncology, Inc.
– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming...
Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer
31 juil. 2018 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Second Quarter 2018 Financial Results
30 juil. 2018 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
02 juil. 2018 16h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 02, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
28 juin 2018 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at JMP Securities Life Sciences Conference
14 juin 2018 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
OncoDNA announces screening collaboration with Kura Oncology
22 mai 2018 07h00 HE
|
Kura Oncology, Inc.
- OncoDNA to support patient enrolment for Kura Oncology’s Phase II trial of tipifarnib- Agreement demonstrates OncoDNA’s biopharma partnership strategy GOSSELIES, Belgium, May 22, 2018 (GLOBE...